A Prospective Study Regarding the Efficacy and Safety of the BNT162b2 Vaccine in Patients With Solid Malignancies Undergoing Systemic Chemotherapy.
In Vivo
; 36(6): 2780-2789, 2022.
Статья
в английский
| MEDLINE | ID: covidwho-2100679
ABSTRACT
BACKGROUND/AIM:
To prospectively evaluate the efficacy and safety of the BNT162b2 vaccine in solid cancer patients undergoing systemic chemotherapy (n=63). PATIENTS ANDMETHODS:
COVID-19 anti-spike protein antibody levels were measured before the first BNT162b2 vaccination, just before the second BNT162b2 vaccination, one month after the second BNT162b2 vaccination, and 3 months after the second BNT162b2 vaccination. Anti-spike protein antibody seropositivity was set at ≥0.8 U/ml.RESULTS:
Colorectal cancer was the most commonly observed primary disease (36.5%). ECOG-PS 0 was observed in the majority (52.4%) of patients. The overall response rate and the median (range) anti-spike protein antibody levels in the whole cohort at 3 months after the second BNT162b2 vaccination were 98.4% (62/63) and 206 (0.4-3,813) U/ml. None of the patients required postponement or discontinuation of systemic chemotherapy because of an adverse reaction.CONCLUSION:
The BNT162b vaccine in solid cancer patients undergoing systemic chemotherapy is effective and safe.ключевые слова
Полный текст:
Имеется в наличии
Коллекция:
Международные базы данных
база данных:
MEDLINE
Основная тема:
Vaccines
/
COVID-19
/
Neoplasms
Тип исследования:
Когортное исследование
/
Экспериментальные исследования
/
Наблюдательное исследование
/
Прогностическое исследование
Темы:
Вакцина
Пределы темы:
Люди
Язык:
английский
Журнал:
In Vivo
Тематика журнала:
Онкология
Год:
2022
Тип:
Статья
Аффилированная страна:
Invivo.13015
Документы, близкие по теме
MEDLINE
...
LILACS
LIS